Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Neurocrine Biosciences (NBIX) stock in plain English

Free brief · no signupStart here
NBIXPublished Nov 13, 2026
Neurocrine Biosciences Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells oral prescription therapies for involuntary movement disorders, chorea, and rare endocrine conditions.
Assets:
Ingrezza franchisePrimary commercial revenue driver for movement disorders
San Diego campusCentralizes research laboratories and executive corporate operations
Specialized sales forceDeploys nationwide teams focused on psychiatry and neurology clinics
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

84
OPS ScoreOperating finances
Latest quote
-3.85%$156.59
$15.85B
23.2×
$3.70B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was NBIX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Neurocrine Biosciences (NBIX) do?

Neurocrine Biosciences Inc (NBIX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells oral prescription therapies for involuntary movement disorders, chorea, and rare endocrine conditions. Discovers and commercializes targeted pharmaceutical treatments for neurological, endocrine, and psychiatric disorders. It is worth $15.85B on the market and sold $3.70B over the last year.

Market cap
$15.85B
P/E ratio
23.2×
Annual sales
$3.70B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 13, 2026

Brands and businesses behind NBIX

  • Ingrezza: Generates revenue by treating adult tardive dyskinesia and chorea linked to Huntington disease through daily oral capsules.
  • Ongentys: Earns revenue by providing an oral adjunctive therapy for patients with Parkinson disease experiencing motor fluctuations.

NBIX’s flags, in plain English

Each flag is a number from Neurocrine Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Low debt

Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 96.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Worth a Look

A single drug, Ingrezza, generates the vast majority of total commercial revenue. Something here could change the picture, so it is worth reading next to the good news.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about NBIX

How big is Neurocrine Biosciences?

Neurocrine Biosciences’ market cap is $15.85B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.70B: what customers paid the company over the last year, before any costs.

What is NBIX’s P/E ratio?

NBIX’s P/E ratio is 23.2×. Investors pay about 23.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with NBIX?

The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Neurocrine Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NBIX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card